San Francisco Giants start brutal stretch of schedule with another fill-in coach

first_imgSAN FRANCISCO — Antoan Richardson’s major league career wasn’t exactly storybook, but the former outfielder is a footnote in one of the greatest chapters Derek Jeter authored.In Jeter’s final at-bat at Yankee Stadium, the future Hall of Famer hit a walk-off single to help the Yankees beat the Orioles in memorable fashion. Richardson was the baserunner who scored on the hit.Richardson appeared in just 22 major league games and his professional career ended in 2016 after he was released from …last_img

Facebook Acting Buggy? You Could Be a Test Subject

first_imgRelated Posts mike melanson Tags:#Facebook#news#web Have you ever been using Facebook and randomly found that you were suddenly unable to do some very basic thing, like update your status? Or comment on and “like” your friends’ statuses? Maybe the design suddenly changed slightly and you were the only one seeing it?Don’t worry, Facebook is a website and websites aren’t haunted, so there’s nothing supernatural at play. Rather, it could be that someone at Facebook is intentionally messing with you to see how you react…but in the end, it’s all for a better user experience.Facebook product designer Adam Mosseri spoke earlier this week at a Design Drink Up at Yelp headquarters about how “design is ‘informed’ by data, and not the sole driver.” During his talk, Mosseri discussed a number of different ways that the world’s largest social network slightly tweaks certain settings for a small percentage of its users. The funny thing about having more than 600 million users, of course, is that even just 1% means 6 million people. According to Mosseri, 2010 was a year of design focused on increasing user engagement. They knew that the number of friends a user had was related to their engagement with the site, but what other factors were driving this engagement?To find out, Facebook’s design team began running different studies. One, informally dubbed the “Yo Momma” study, consisted of interviewing new mothers about their experience on Facebook. Just your garden variety user study, right? Another study, however, turned off the ability to like or comment on friends’ status updates for a “small percent of users.” That small percent accounted for “several million” users, said Mosseri.Facebook ran the study for two weeks, before finally ending it early because users were getting so annoyed at their situation. The company found that the “bug” caused a 7% drop in sessions and a 10% drop in time on the site for affected users. These users did, however, find a way of expressing their grievances.So, the next time something goes completely awry with Facebook and everyone looks at you like you’re crazy, worry not – it might not be you, your computer or the wires in-between. It might just be the friendly folks over at Facebook seeing how you react so they can try to make things better. Some other fun facts:Out of 100 people that try to upload a photo to Facebook:89% reach the starting point – the photo uploader.58% select the photos they want to upload.57% actually press the upload button.54% succeed in uploading photos in one shot.70% of people eventually succeed by the end of the day.The last time Mosseri gave the talk, only 48% of people succeeded in uploading photos in one shot.There is incredible anxiety for users in updating their status:Out of users that enter three or more characters into the status update box, 17% don’t post anything at all.“That’s one in six people who attempt to post something but don’t,” said Mosseri. “That’s pretty crazy.”There are “way more people using Facebook on feature phones than smartphones,” but those using smartphones are “way more engaged.” The Dos and Don’ts of Brand Awareness Videoscenter_img Facebook is Becoming Less Personal and More Pro… A Comprehensive Guide to a Content Audit Guide to Performing Bulk Email Verificationlast_img read more

Saunders and Monroe want Golovkin-Alvarez shot

first_imgMOST READ E.T. returns to earth, reunites with grown-up Elliott in new ad  BSP sees higher prices in November, but expects stronger peso, low rice costs to put up fight Read Next “He hasn’t had to go into a lion’s den with all these screaming fans against him.” Saunders’ promoter Frank Warren is confident his boxer will face the winner of Golovkin-Alvarez should he beat Monroe Jr.“If Bill comes through he will fight the winner of Canelo-Golovkin,” said Warren. “It’s all in his hands now. He knows what he gets out of this fight if he wins and I believe he will deliver.”– ‘Shot at redemption’ –Monroe, 30, is boxing for the first time in a year and has registered two points-wins since being stopped in six rounds by knockout specialist Golovkin.“He took a beating before and if he quit before when there were three belts on the line, he will certainly quit when there’s one belt on the line,” said Saunders.Monroe, from New York, refused to be drawn into trash talk but is hoping Golovkin beats Alvarez so he can have a re-match.“It’s a shot at redemption,” said Monroe. “I think Canelo is just going to win but I want Triple G (Golovkin) to win so I can get him back.“If you look at my fight with Golovkin and his fight against Kell Brook and Danny Jacobs, he doesn’t deal with fast fighters.“I’ve had a 12 week camp for Billy Joe, but I only got six weeks’ notice for Golovkin. I never had big backers and money guys in my corner to make things happen, so when a shot like that comes up you take it.”He added: “Billy Joe has had a great promoter like Frank Warren in his corner. All the fights have been in his own backyard. Willie Monroe Jr. of the US is checked by the referee after being knocked down in the first round by Gennady Golovkin from Kazakhstan during their Middleweight World Championship bout at the Forum Arena in Los Angeles, California on May 16, 2015. Golovkin won the fight by knocking out Monroe Jr. in the sixth round. AFP PHOTO / MARK RALSTON / AFP PHOTO / MARK RALSTONGennady Golovkin and Saul ‘Canelo’ Alvarez’s eagerly-anticipated bout will be watched by a global television audience, but it is not the only world middleweight title fight on Saturday.Billy Joe Saunders’ second defense of his World Boxing Organization belt against Willie Monroe Jr. in London will not attract the same attention or glamour but is nevertheless significant since the winner is likely to face the victor of Golovkin-Alvarez clash, which takes place a few hours later in Las Vegas.ADVERTISEMENT Fire hits houses in Mandaluyong City LATEST STORIES Frontrow holds fun run to raise funds for young cancer patients  Nonong Araneta re-elected as PFF presidentcenter_img Great Britain’s Billy Joe Saunders (L) is declared winner after defeating Turkey’s Adem Kilicci during their 2008 Olympic Games Welterweight (69 kg) boxing bout on August 10, 2008 in Beijing. AFP PHOTO JACQUES DEMARTHON / AFP PHOTO / JACQUES DEMARTHON“You can say lack of motivation but when you’re in touching distance of something great, that alone gives me motivation,” Saunders told reporters on a conference call from his training base in Fuerteventura, one of the Spanish Canary Islands.“The way the Ingles go about their business is second to none. My fitness is on a different level. I’m fit enough now to fight 15 rounds, every minute of every round. That alone boosts my confidence by leaps and bounds.“I know what is around the corner, I want to test myself against one of the greats. Willie had his chance (against Golovkin in May, 2015). I want to beat Willie Monroe in a better way than Golovkin did.”Golovkin, 35, and Alvarez, 27, are recognised as the best middleweights in the division and Saunders thinks the champion will prevail this weekend.“I think it will be a very close fight but Canelo looks like he has overdone it in training, he looked fatigued in training and he’s overdone it,’ said Saunders, from Hertfordshire, northwest of London.ADVERTISEMENT WATCH: Streetboys show off slick dance moves in Vhong Navarro’s wedding Don’t miss out on the latest news and information. Trending Articles PLAY LIST 00:50Trending Articles00:50Trending Articles05:18After the Typhoon Part 201:37Protesters burn down Iran consulate in Najaf01:47Panelo casts doubts on Robredo’s drug war ‘discoveries’01:29Police teams find crossbows, bows in HK university01:35Panelo suggests discounted SEA Games tickets for students02:49Robredo: True leaders perform well despite having ‘uninspiring’ boss02:42PH underwater hockey team aims to make waves in SEA Games Brace for potentially devastating typhoon approaching PH – NDRRMC LOOK: Loisa Andalio, Ronnie Alonte unwind in Amanpulo for 3rd anniversary Lyceum averts disaster, escapes Arellano to stay unbeaten Golovkin, from Kazakhstan but based in California, defends the other three versions of the world title (World Boxing Council, World Boxing Association and International Boxing Federation) against Mexico’s Alvarez in a clash between boxing’s biggest stars now that Floyd Mayweather Jr has gone back into retirement.For Saunders, there can be no more excuses about motivation after an inactive and frustrating reign as champion. The 28-year-old English boxer won the WBO belt from Ireland’s Andy Lee in December 2015 but due to injuries and postponements has only fought once since, an unimpressive points win over Artur Akavov at a leisure centre in Scotland in December.FEATURED STORIESSPORTSWATCH: Drones light up sky in final leg of SEA Games torch runSPORTSSEA Games: Philippines picks up 1st win in men’s water poloSPORTSMalditas save PH from shutoutBut Saunders (24 wins, 0 defeats, 12 KOs) feels rejuvenated and credits new trainer Dominic Ingle with improving his conditioning ahead of facing American Monroe (21 wins, 2 defeats, 6 KOs).‘Confidence boost’ View commentslast_img read more

April 3 2001 Pouring a siltcast panel Construct

first_imgApril 3, 2001Pouring a silt-cast panel:Construction Crewmember Jeff Buderer, mixes concrete while MarchWorkshopper Joost Zwart transports it to the prepared formwork. [Photos andtext by Jennifer Thornton] MarchWorkshopper Cheyne Roose helps to prep the formwork for the pour. Habitat Manager David Tollas (far left), construction crewmembers andWorkshoppers, pour concrete into the formwork.last_img

Google has selected TiVo Music Metadata to provide

first_imgGoogle has selected TiVo Music Metadata to provide artist data and images for YouTube Red, YouTube Music and the Google Play Music store.Through the deal, YouTube and Google will be able to connect music videos to artist pictures and songs, offering what TiVo described as a “more immersive entertainment experience”.“In addition to the incredible range of our collection, TiVo Music Metadata has a unique ability to go beyond traditional tracking, linking musical library content with other relevant artist or album info, which provides a wider span of context for the listener,” said Roz Ho, senior vice president and general manager, consumer and metadata, TiVo.“The dynamic features of our metadata made it the ideal fit for Google’s musical platforms, allowing them to create stronger entertainment experiences.”The news comes weeks after YouTube CEO Susan Wojcicki said that YouTube Red is due to be rolled out to around 100 countries this year.Speaking at the Code Media conference in California, Wojcicki described Red as “really a music service,” which it now plans to expand into many more markets after agreeing music licensing deals.TiVo Music Metadata claims to cover 34 million tracks worldwide that are refreshed daily.last_img read more

RTL aims to grow the number of paying subscribers

first_imgRTL aims to grow the number of paying subscribers to its SVOD services to three million and to grow revenue from video-on-demand to €360 million by 2021, after the number of paying subscribers to its services passed the one million mark at the end of last year.Bert HabetsCEO Bert Habets said the group would focus on creating “local streaming champions” as well as strengthening content creation. RTL will invest at least an additional €350 million in expanding its streaming offerings over the next three years, including €300 million to be invested in content across all genres.Habets emphasised that the investment should not have a significant impact on RTL’s bottom line.“As our streaming services are deeply integrated in our families of TV channels, these investments will generate sizeable additional revenue and will thus have limited impact on our operating profit. Every investment in local, exclusive content is an investment for the long run, strengthening both our linear TV channels and streaming services. In other words: we will continue to generate very healthy profit margins,” he said.RTL’s paying subscriber base, combining TV Now Premium in Germany and Videoland in the Netherlands, passed the one million mark at the end of 2018, and the company aims to triple this within three years. TV Now Premium’s base grew by 43.5%, while Videoland grew by 134.9%, driven by local originals such as Temptation Island VIPs and crime series Mocro Maffia, both made exclusively for the service.Habets said that the group may “increase our ambitions in this space” if SVOD growth exceeds expectations.Habets said that RTL also aims to generate more than €500 million from international drama productions from Fremantle by 2021, adding that drama series were “also key for the expansion of our streaming services”.The group posted solid full-year 2018 revenue figures that were boosted by its digital offerings and its Fremantle production unit. Group revenue was up 2.1% to €6.5 billion, driven by its digital businesses, Fremantle and a strong performance by RTL Nederland. Digital revenue was €985 million, up from €826 million, and now represents 15.1% of the total.RTL said that only 45.8% of its revenue now came from TV advertising, with the remainder coming from activities such as content and platform revenue as well as digital.RTL posted EBITDA of €1.38 billion, down 5.7% as the result of the one-off sale of the group’s Paris buildings in 2017, but up 0.7% on an adjusted basis.last_img read more

STARTERS ORDERS Wednesday

first_img[dropcap]W[/dropcap]elcome to Starters Orders. Our daily midday update from the trading room at Star Sports with our key market movers for the day across all sports.Wednesday 30 JulyRACING2.30 GoodwoodSomewhat 9/2 > 7/23.05 GoodwoodKingman 4/9 > 1/34.35 PerthMister Nibbles 3/1 > 2/14.50 GoodwoodPrinciple Equation 8/1 > 4/16.00 LeicesterStroll Patrol 5/2 > 11/86.05 GalwaySister Slew 8/1 > 7/2What’s your view?CALL STAR SPORTS ON 08000 521 321last_img

Children are attuned to social bias at a surprisingly young age finds

first_imgReviewed by James Ives, M.Psych. (Editor)Jan 24 2019In a Developmental Science study of preschool-aged children, implicit and explicit evaluations of Black boys were less positive than evaluations of Black girls, White boys, or White girls.This “gendered racial bias” was exhibited by both White and non-White children and was not correlated with their exposure to diversity. It also mirrors social bias observed in adults.The study, which reveals the earliest evidence of bias at the intersection of race and gender, underscores the importance of addressing bias in the first years of life.”Our results suggest that children are attuned to nuanced patterns of social bias at a surprisingly young age,” said lead author Danielle Perszyk, of Northwestern University. “This means that efforts to counter such bias must begin very early in children’s development.”Source: https://newsroom.wiley.com/press-release/developmental-science/study-reveals-bias-children-even-they-reach-kindergartenlast_img read more

Huge Malaria vaccine trial in Malawi

first_imgPeter Sands, Executive Director of the Global Fund in his statement added, “To step up the fight against malaria, we need every available tool. If this pilot shows that RTS,S is a cost-effective tool against malaria, it will help us save more children’s lives.” Dr Seth Berkley, CEO of Gavi in his statement said, “Malaria is still one of the biggest killers of children worldwide, taking the lives of over 200,000 children every year. These pilots will be crucial to determine the part this vaccine could play in reducing the burden this disease continues to place on the world’s poorest countries.” The vaccine known as RTS,S or Mosquirix, would be administered to children up to 2 years of age. After Malawi, the vaccine would be introduced in its pilot trial phase in Ghana and Kenya in the coming weeks. In these African countries malaria remains a menace and kills with an alarming frequency of one child every two minutes. In Africa, over 250,000 children die due to malaria annually. The risks of dying due to malaria and its complications are highest among children under the age of five years. Across the world, malaria kills 435,000 people annually of which most are children says WHO. The team leading the pilot trial would roll out the programme and help to generate information and experience with the RTS,S malaria vaccine so that WHO can devise its policy recommendations regarding the vaccine. The utility and efficacy of the vaccine in reducing childhood deaths, safety of the vaccines, if the parents were willing to bring their children for the routine four doses of the vaccine and its general acceptance would all be studied.WHO officials add, that this new malaria vaccine would be part of the malaria control programme. WHO recommends other major measures for malaria control including insecticide-treated bed nets, use of insecticides indoors and routine testing for malaria in case of fever and its early treatment.This pilot programme is a collaboration between the WHO and ministries of health in Ghana, Kenya and Malawi along with PATH, a non-profit organization and makers of the vaccine GSK. GSK is donating up to 10 million vaccine doses for this pilot project. This pilot project is receiving financial support from Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and Unitaid. Contributions in kind are being provided by WHO, PATH and GSK. Steve Davis, President and CEO of PATH said in a statement, “We salute WHO and Malawi for their leadership in realizing this historic milestone and we look forward to the start of vaccination in Ghana, and then Kenya later this year. A vaccine for malaria is among many innovations needed to bring an end to this disease, and we proudly stand with all countries and our many partners in progressing towards a malaria-free world.” Dr Matshidiso Moeti, WHO Regional Director for Africa, in a statement said, “Malaria is a constant threat in the African communities where this vaccine will be given. The poorest children suffer the most and are at highest risk of death. We know the power of vaccines to prevent killer diseases and reach children, including those who may not have immediate access to the doctors, nurses and health facilities they need to save them when severe illness comes. This is a day to celebrate as we begin to learn more about what this tool can do to change the trajectory of malaria through childhood vaccination.” Malaria vaccine trial in Malawi. Image Credit: WHO This malaria vaccine took three decades to make say researchers. Until now it remains the only vaccine against malaria. Phase 3 clinical trials with the vaccine have been conducted in Africa between 2009 and 2014. These clinical trials with this vaccine show that this vaccine could prevent 40 percent of malaria cases and 30 percent of fatal severe malaria cases. Dr David Schellenberg, one of the researchers who helped develop the vaccine said in a statement, “There were seven countries participating in a large trial where over 15,000 children participated. [The trial] showed pretty clearly that this vaccine is safe and it is efficacious in terms of its ability to prevent clinical malaria episodes and also severe malaria episodes.”#Malawi 🇲🇼: A baby girl named Gloria was first in line for a #malariavaccine at the Muotcha HIV Testing & Counseling Centre in the town of Balaka. pic.twitter.com/EYGh46XcB7— WHO African Region (@WHOAFRO) April 24, 2019 Similarly Lelio Marmora, Executive Director of Unitaid added, “The malaria vaccine is an exciting innovation that complements the global health community’s efforts to end the malaria epidemic. It is also a shining example of the kind of inter-agency coordination that we need. We look forward to learning how the vaccine can be integrated for greatest impact into our work.” According to WHO Director-General Dr Tedros Adhanom Ghebreyesus in a statement, “We have seen tremendous gains from bed nets and other measures to control malaria in the last 15 years, but progress has stalled and even reversed in some areas. We need new solutions to get the malaria response back on track, and this vaccine gives us a promising tool to get there. The malaria vaccine has the potential to save tens of thousands of children’s lives.” Further Reading What is Malaria? Malaria Causes Malaria Mechanism Malaria Diagnosis Malaria Prevention Malaria Treatment Malaria Epidemiology Malaria Society And Culture Malaria Symptoms The pilot programme is slated to reach around 360,000 children annually in the three target nations. The areas covered would be regions where malaria transmission is high and the vaccine would be of greater help say officials. There would be four doses of the vaccine for each child – 3 doses to be administered between 5 and 9 months of age and the fourth dose to be administered at around the age of 2 years.A PATH white paper on this project says, “Looking ahead The pilot implementation was designed as a six-year program, including preparation, and the evaluations are now expected to be completed by 2023. Its goal is to enable an updated WHO policy recommendation on the possible broader use of RTS,S in African children by generating additional evidence on feasibility, impact, and safety—all in the context of routine use.” By Dr. Ananya Mandal, MDApr 24 2019This week the African nation of Malawi became one of the first of the planned three to launch a pilot trial for a novel vaccine against malaria. The news and the efforts were lauded by the World Health Organization (WHO). Dr Thomas Breuer, Chief Medical Officer of GSK Vaccines in a statement said, “Delivering the world’s first malaria vaccine will help reduce the burden of one of the most pressing health challenges globally. This novel tool is the result of GSK employees collaborating with their partners, applying the latest in vaccine science to contribute to the fight against malaria. We look forward to seeing the results of the pilot, and in parallel, are working with WHO and PATH to secure the vaccine’s sustained global health impact in the future.”last_img read more

Circulating tumor DNA can help detect treatment options for ovarian cancer subtype

first_imgReviewed by James Ives, M.Psych. (Editor)May 6 2019According to a new research, circulating tumor DNA can be used detect treatment options for ovarian cancer patients who don’t benefit from chemotherapy.High-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer. The HGSOC tumors consist of several heterogeneous cell populations with a large number of mutations. This genetic variability makes it difficult to find drugs that would kill all the cancer cells, and to which the cells would not become resistant during treatment.Over half of the patients diagnosed with high-grade serous ovarian cancer die within five years of diagnosis, that is, annually more than 150000 women globally. To improve the efficacy of HGSOC treatment, a research group from University of Helsinki, together with researchers from University of Turku and Turku University Hospital, have now studied the use of circulating tumor DNA in finding precision medicine-based treatments for the disease.Circulating tumor DNA refers to tumor-derived cell-free DNA in the bloodstream. Circulating tumor DNA detection is a minimally invasive technique that offers dynamic “molecular snapshots” of genomic alterations in cancer.”Analyzing circulating tumor DNA enables us to detect genomic alterations also in late stage cancers in which taking biopsies from the tumor is difficult or even impossible. In the current research, we demonstrated that circulating tumor DNA can be used to monitor the patient responses to treatment, and find drug combinations to target the Achilles’ heels of the tumor’s genomic profile,” says Professor Sampsa Hautaniemi, director of the Systems Oncology Research Program in the Faculty of Medicine at University of Helsinki.Related StoriesSpecial blood test may predict relapse risk for breast cancer patientsBacteria in the birth canal linked to lower risk of ovarian cancerUsing machine learning algorithm to accurately diagnose breast cancerThe results were published in JCO Precision Oncology.Hautaniemi’s research group has implemented a clinical circulating tumor DNA workflow to detect clinically actionable alterations in more than 500 cancer-related genes.In the present study, the researchers analyzed 78 circulating tumor DNA samples from 12 ovarian cancer patients before, during and after the treatment using bioinformatics analysis, and in-house Translational Oncology Knowledgebase to detect clinically actionable genomic alterations.DNA alterations associated with clinically available drugs were detected in 58% of the patients. The treatment of one patient has already been tailored successfully based on the results. For the other patients the results may be useful if their cancer relapses.The results demonstrate a proof-of-concept for using circulating tumor DNA to guide clinical decisions. Furthermore, the results show that longitudinal circulating tumor DNA samples can be used to identify poor-responding patients after first cycles of chemotherapy.In addition, the researchers provide the first comprehensive, open-source circulating tumor DNA workflow for detecting clinically actionable alterations in solid cancers.”The prognosis of ovarian cancer patients is still poor. However, the future looks brighter as research has discovered targeted therapies for the genomic alterations also in ovarian cancer tumors. We are currently in the forefront of the precision medicine for ovarian cancer. Our goal is to find out how ovarian cancer becomes resistant to current treatments, and use this knowledge in finding more effective precision treatments,” Hautaniemi says. Sources:The University of Helsinki.Journal reference:Jaana Oikkonen et al. (2019) Prospective longitudinal ctDNA workflow reveals clinically actionable alterations in ovarian cancer. JCO Precision Oncology. doi.org/10.1200/PO.18.00343.last_img read more